{"transactions":[{"id":2961000,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.01 Par Value","published_at":"2020-12-02T22:33:23.000Z","date":"2020-11-30","kind":"grant","acquired":true,"shares":227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020."}],"balance_after":48839,"source":{"system":"sec-edgar","filing":"0001225208-20-014152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000122520820014152/doc4.xml","form_type":"4"}},{"id":3041312,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.01 Par Value","published_at":"2020-09-02T21:36:18.000Z","date":"2020-08-31","kind":"grant","acquired":true,"shares":267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020."}],"balance_after":48612,"source":{"system":"sec-edgar","filing":"0001225208-20-011220","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000122520820011220/doc4.xml","form_type":"4"}},{"id":3127251,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.01 Par Value","published_at":"2020-06-02T21:12:09.000Z","date":"2020-05-29","kind":"grant","acquired":true,"shares":240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020."}],"balance_after":48345,"source":{"system":"sec-edgar","filing":"0001225208-20-008486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000122520820008486/doc4.xml","form_type":"4"}},{"id":3233106,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.01 Par Value","published_at":"2020-03-03T22:06:50.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019."}],"balance_after":48105,"source":{"system":"sec-edgar","filing":"0001225208-20-004182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000122520820004182/doc4.xml","form_type":"4"}},{"id":3355998,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.01 Par Value","published_at":"2019-12-03T00:41:43.000Z","date":"2019-11-29","kind":"grant","acquired":true,"shares":237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019."}],"balance_after":47846,"source":{"system":"sec-edgar","filing":"0001225208-19-015090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000122520819015090/doc4.xml","form_type":"4"}},{"id":3423414,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.01 Par Value","published_at":"2019-09-04T21:34:16.000Z","date":"2019-08-30","kind":"grant","acquired":true,"shares":308,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019."}],"balance_after":47609,"source":{"system":"sec-edgar","filing":"0001225208-19-012166","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000122520819012166/doc4.xml","form_type":"4"}},{"id":3502625,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.01 Par Value","published_at":"2019-06-04T21:14:00.000Z","date":"2019-05-31","kind":"grant","acquired":true,"shares":320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019."}],"balance_after":47301,"source":{"system":"sec-edgar","filing":"0001225208-19-008810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000122520819008810/doc4.xml","form_type":"4"}},{"id":3619496,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.01 Par Value","published_at":"2019-03-04T23:38:44.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018."}],"balance_after":46981,"source":{"system":"sec-edgar","filing":"0001225208-19-004404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000122520819004404/doc4.xml","form_type":"4"}},{"id":3719230,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2018-12-27T00:18:09.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":15426,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. (\"New Cigna\"), was acquired pursuant to the consummation of the mergers (collectively, the \"Merger\") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) (\"Cigna\"), Express Scripts Holding Company (\"Express Scripts\"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger (\"New Cigna\"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the \"Merger Agreement\"), pursuant to which, at the effective time of the Merger (the \"Effective Time\"), (continued in following footnote)"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna.  As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna.  In the Merger, each share of Cigna common stock, par value $0.25 per share (\"Cigna Common Stock\"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna (\"New Cigna Common Stock\").  The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. (\"New Cigna\"), was acquired pursuant to the consummation of the mergers (collectively, the \"Merger\") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) (\"Cigna\"), Express Scripts Holding Company (\"Express Scripts\"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger (\"New Cigna\"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the \"Merger Agreement\"), pursuant to which, at the effective time of the Merger (the \"Effective Time\"), (continued in following footnote)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna.  As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna.  In the Merger, each share of Cigna common stock, par value $0.25 per share (\"Cigna Common Stock\"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna (\"New Cigna Common Stock\").  The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."}],"balance_after":15426,"derivative":{"underlying":"Common Stock, $0.01 Par Value","underlying_shares":15426},"source":{"system":"sec-edgar","filing":"0001567619-18-008707","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000156761918008707/doc1.xml","form_type":"4"}},{"id":3719229,"issuer":{"id":550,"kind":"organization","name":"Cigna Group","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 Par Value","published_at":"2018-12-27T00:18:09.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":46709,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. (\"New Cigna\"), was acquired pursuant to the consummation of the mergers (collectively, the \"Merger\") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) (\"Cigna\"), Express Scripts Holding Company (\"Express Scripts\"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger (\"New Cigna\"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the \"Merger Agreement\"), pursuant to which, at the effective time of the Merger (the \"Effective Time\"), (continued in following footnote)"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna.  As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna.  In the Merger, each share of Cigna common stock, par value $0.25 per share (\"Cigna Common Stock\"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna (\"New Cigna Common Stock\").  The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. (\"New Cigna\"), was acquired pursuant to the consummation of the mergers (collectively, the \"Merger\") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) (\"Cigna\"), Express Scripts Holding Company (\"Express Scripts\"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger (\"New Cigna\"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the \"Merger Agreement\"), pursuant to which, at the effective time of the Merger (the \"Effective Time\"), (continued in following footnote)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna.  As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna.  In the Merger, each share of Cigna common stock, par value $0.25 per share (\"Cigna Common Stock\"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna (\"New Cigna Common Stock\").  The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30."}],"balance_after":46709,"source":{"system":"sec-edgar","filing":"0001567619-18-008707","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739940/000156761918008707/doc1.xml","form_type":"4"}},{"id":3720306,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2018-12-26T18:41:14.000Z","date":"2018-12-20","kind":"disposition_to_issuer","acquired":false,"shares":15426,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash.  Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash.  Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition in connection with the consummation of the mergers (collectively, the \"Merger\") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) (\"Cigna\"), Express Scripts Holding Company (\"Express Scripts\"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger (\"New Cigna\"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the \"Merger Agreement\"), pursuant to which, at the effective time of the Merger (the \"Effective Time\"), (continued in following footnote)"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna.  As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna.  In the Merger, each share of Cigna common stock, par value $0.25 per share (\"Cigna Common Stock\"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna (\"New Cigna Common Stock\").  The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash.  Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition in connection with the consummation of the mergers (collectively, the \"Merger\") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) (\"Cigna\"), Express Scripts Holding Company (\"Express Scripts\"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger (\"New Cigna\"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the \"Merger Agreement\"), pursuant to which, at the effective time of the Merger (the \"Effective Time\"), (continued in following footnote)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna.  As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna.  In the Merger, each share of Cigna common stock, par value $0.25 per share (\"Cigna Common Stock\"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna (\"New Cigna Common Stock\").  The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash.  Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash.  Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash.  Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash."}],"balance_after":0,"derivative":{"underlying":"Common Stock, $.25 Par Value","underlying_shares":15426},"source":{"system":"sec-edgar","filing":"0001567619-18-008649","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/701221/000156761918008649/doc1.xml","form_type":"4"}},{"id":3720305,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $.25 Par Value","published_at":"2018-12-26T18:41:14.000Z","date":"2018-12-20","kind":"disposition_to_issuer","acquired":false,"shares":46709,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition in connection with the consummation of the mergers (collectively, the \"Merger\") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) (\"Cigna\"), Express Scripts Holding Company (\"Express Scripts\"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger (\"New Cigna\"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the \"Merger Agreement\"), pursuant to which, at the effective time of the Merger (the \"Effective Time\"), (continued in following footnote)"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna.  As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna.  In the Merger, each share of Cigna common stock, par value $0.25 per share (\"Cigna Common Stock\"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna (\"New Cigna Common Stock\").  The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition in connection with the consummation of the mergers (collectively, the \"Merger\") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) (\"Cigna\"), Express Scripts Holding Company (\"Express Scripts\"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger (\"New Cigna\"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the \"Merger Agreement\"), pursuant to which, at the effective time of the Merger (the \"Effective Time\"), (continued in following footnote)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna.  As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna.  In the Merger, each share of Cigna common stock, par value $0.25 per share (\"Cigna Common Stock\"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna (\"New Cigna Common Stock\").  The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-18-008649","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000156761918008649/doc1.xml","form_type":"4"}},{"id":3745116,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.25 Par Value","published_at":"2018-12-04T18:28:35.000Z","date":"2018-11-30","kind":"grant","acquired":true,"shares":201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018."}],"balance_after":46709,"source":{"system":"sec-edgar","filing":"0001225208-18-016221","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000122520818016221/doc4.xml","form_type":"4"}},{"id":3826484,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.25 Par Value","published_at":"2018-09-05T17:49:51.000Z","date":"2018-08-31","kind":"grant","acquired":true,"shares":238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018."}],"balance_after":46508,"source":{"system":"sec-edgar","filing":"0001225208-18-013183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000122520818013183/doc4.xml","form_type":"4"}},{"id":3902595,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2018-06-07T17:40:14.000Z","date":"2018-06-06","kind":"disposition_to_issuer","acquired":false,"shares":7633,"price":134.5,"value":1026638.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding phantom stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested phantom stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such phantom stock units as of immediately prior to the effective time of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding phantom stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested phantom stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such phantom stock units as of immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding phantom stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested phantom stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such phantom stock units as of immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding phantom stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested phantom stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such phantom stock units as of immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7633},"source":{"system":"sec-edgar","filing":"0001104659-18-038962","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/866121/000110465918038962/a4.xml","form_type":"4"}},{"id":3902594,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2018-06-07T17:40:14.000Z","date":"2018-06-06","kind":"disposition_to_issuer","acquired":false,"shares":15566,"price":134.5,"value":2093627.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding deferred stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested deferred stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such deferred stock units as of immediately prior to the effective time of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding deferred stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested deferred stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such deferred stock units as of immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding deferred stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested deferred stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such deferred stock units as of immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, effective as of the effective time of the Merger, outstanding deferred stock units became fully vested in accordance with the terms of the Merger Agreement and were converted into the right to receive a cash payment equal to the number of shares of Company common stock underlying the vested deferred stock units multiplied by the per share merger consideration of $134.50, less any applicable withholding for taxes, payable in accordance with, and subject to, the deferral elections applicable to such deferred stock units as of immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15566},"source":{"system":"sec-edgar","filing":"0001104659-18-038962","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/866121/000110465918038962/a4.xml","form_type":"4"}},{"id":3902593,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-07T17:40:14.000Z","date":"2018-06-06","kind":"disposition_to_issuer","acquired":false,"shares":1000,"price":134.5,"value":134500.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 17, 2017 (the \"Merger Agreement\"), among Northrop Grumman Innovation Systems, Inc. (formerly known as Orbital ATK, Inc.) (the \"Company\"), Northrop Grumman Corporation and Neptune Merger, Inc., a wholly owned subsidiary of Northrop Grumman Corporation (\"Sub\"), effective as of immediately prior to the effective time of the merger of the Company and Sub (the \"Merger\"), these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $134.50."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-038962","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/866121/000110465918038962/a4.xml","form_type":"4"}},{"id":3902592,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-07T17:40:14.000Z","date":"2018-06-06","kind":"disposition_to_issuer","acquired":false,"shares":3000,"price":134.5,"value":403500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 17, 2017 (the \"Merger Agreement\"), among Northrop Grumman Innovation Systems, Inc. (formerly known as Orbital ATK, Inc.) (the \"Company\"), Northrop Grumman Corporation and Neptune Merger, Inc., a wholly owned subsidiary of Northrop Grumman Corporation (\"Sub\"), effective as of immediately prior to the effective time of the merger of the Company and Sub (the \"Merger\"), these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $134.50."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-038962","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000110465918038962/a4.xml","form_type":"4"}},{"id":3909727,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.25 Par Value","published_at":"2018-06-04T17:28:00.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018."}],"balance_after":46270,"source":{"system":"sec-edgar","filing":"0001225208-18-010122","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000122520818010122/doc4.xml","form_type":"4"}},{"id":3929379,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2018-05-17T13:04:59.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":18.2836,"price":133.28,"value":2436.838208,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."}],"balance_after":7633,"derivative":{"underlying":"Common Stock","underlying_shares":18.2836},"source":{"system":"sec-edgar","filing":"0001140361-18-024355","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000114036118024355/doc1.xml","form_type":"4"}},{"id":3990803,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2018-03-19T19:22:47.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":18.4079,"price":132.06,"value":2430.947274,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."}],"balance_after":7615,"derivative":{"underlying":"Common Stock","underlying_shares":18.4079},"source":{"system":"sec-edgar","filing":"0001140361-18-014142","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000114036118014142/doc1.xml","form_type":"4"}},{"id":4022415,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.25 Par Value","published_at":"2018-03-02T17:25:11.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's preliminary proxy statement filed with the SEC on March 2, 2018."}],"balance_after":46005,"source":{"system":"sec-edgar","filing":"0001225208-18-005160","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000122520818005160/doc4.xml","form_type":"4"}},{"id":4145293,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.25 Par Value","published_at":"2017-12-04T18:04:52.000Z","date":"2017-11-30","kind":"grant","acquired":true,"shares":212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017."}],"balance_after":45776,"source":{"system":"sec-edgar","filing":"0001225208-17-018126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000122520817018126/doc4.xml","form_type":"4"}},{"id":4145138,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2017-12-04T14:57:12.000Z","date":"2017-12-01","kind":"grant","acquired":true,"shares":18.3801,"price":131.94,"value":2425.070394,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."}],"balance_after":7597,"derivative":{"underlying":"Common Stock","underlying_shares":18.3801},"source":{"system":"sec-edgar","filing":"0001140361-17-044802","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000114036117044802/doc1.xml","form_type":"4"}},{"id":4202773,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2017-09-25T13:39:45.000Z","date":"2017-09-21","kind":"grant","acquired":true,"shares":18.2734,"price":132.39,"value":2419.215426,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."}],"balance_after":7578,"derivative":{"underlying":"Common Stock","underlying_shares":18.2734},"source":{"system":"sec-edgar","filing":"0001140361-17-036308","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000114036117036308/doc1.xml","form_type":"4"}},{"id":4218951,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.25 Par Value","published_at":"2017-09-05T17:07:39.000Z","date":"2017-08-31","kind":"grant","acquired":true,"shares":247,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017."}],"balance_after":45564,"source":{"system":"sec-edgar","filing":"0001225208-17-014581","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000122520817014581/doc4.xml","form_type":"4"}},{"id":4235724,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2017-08-14T20:03:33.000Z","date":"2017-08-10","kind":"grant","acquired":true,"shares":1133,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person has elected to defer the receipt of 1,133 shares of common stock granted pursuant to the Non-Employee Director Stock Program under the Issuer's 2015 Stock Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converts to common stock 1-for-1."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person has elected to defer the receipt of 1,133 shares of common stock granted pursuant to the Non-Employee Director Stock Program under the Issuer's 2015 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred stock units are to be settled 100% in common stock as soon as practicable after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The deferred stock units are to be settled 100% in common stock as soon as practicable after the reporting person ceases to be a director of the Issuer."}],"balance_after":15566,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1133},"source":{"system":"sec-edgar","filing":"0001140361-17-032167","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000114036117032167/doc1.xml","form_type":"4"}},{"id":4274919,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2017-06-22T16:35:57.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":23.9242,"price":100.8,"value":2411.55936,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors. The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."}],"balance_after":7560,"derivative":{"underlying":"Common Stock","underlying_shares":23.9242},"source":{"system":"sec-edgar","filing":"0001140361-17-025873","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000114036117025873/doc1.xml","form_type":"4"}},{"id":4297191,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.25 Par Value","published_at":"2017-06-02T18:31:47.000Z","date":"2017-05-31","kind":"grant","acquired":true,"shares":279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017."}],"balance_after":45317,"source":{"system":"sec-edgar","filing":"0001225208-17-010846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000122520817010846/doc4.xml","form_type":"4"}},{"id":4373037,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2017-03-24T16:37:34.000Z","date":"2017-03-24","kind":"grant","acquired":true,"shares":24.3003,"price":98.92,"value":2403.785676,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors.  The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors.  The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors.  The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."}],"balance_after":7536,"derivative":{"underlying":"Common Stock","underlying_shares":24.3003},"source":{"system":"sec-edgar","filing":"0001104659-17-019180","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000110465917019180/a4.xml","form_type":"4"}},{"id":4412166,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.25 Par Value","published_at":"2017-03-02T17:48:22.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 72 of Cigna's proxy statement filed with the SEC on March 18, 2016."}],"balance_after":45038,"source":{"system":"sec-edgar","filing":"0001225208-17-005389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000122520817005389/doc4.xml","form_type":"4"}},{"id":4536282,"issuer":{"id":161580,"kind":"organization","name":"Cigna Holding Co","symbol":"CI"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true}}],"security":"Common Stock, $.25 Par Value","published_at":"2016-12-02T17:09:34.000Z","date":"2016-11-30","kind":"grant","acquired":true,"shares":333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock.  Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service.  For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 72 of Cigna's proxy statement filed with the SEC on March 18, 2016."}],"balance_after":44736,"source":{"system":"sec-edgar","filing":"0001225208-16-042626","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/701221/000122520816042626/doc4.xml","form_type":"4"}},{"id":4538089,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2016-12-01T12:43:35.000Z","date":"2016-12-01","kind":"grant","acquired":true,"shares":26.3173,"price":85.33,"value":2245.655209,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors.  The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors.  The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors.  The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."}],"balance_after":7512,"derivative":{"underlying":"Common Stock","underlying_shares":26.3173},"source":{"system":"sec-edgar","filing":"0001104659-16-159996","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000110465916159996/a4.xml","form_type":"4"}},{"id":4597565,"issuer":{"id":165900,"kind":"organization","name":"Northrop Grumman Innovation Systems, Inc.","symbol":"OA"},"owners":[{"id":144954,"kind":"person","name":"MARTINEZ ROMAN IV","position":1,"cik":"0001276303","reported_name":"MARTINEZ ROMAN IV","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units","published_at":"2016-09-22T19:05:04.000Z","date":"2016-09-22","kind":"grant","acquired":true,"shares":30.2201,"price":74.01,"value":2236.589601,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors.  The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors.  The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These securities were acquired through the deemed reinvestment of dividend equivalents in the form of additional Phantom Stock Units credited to the reporting person's account under the Issuer's Deferred Fee Plan for Non-Employee Directors.  The Phantom Stock Units are to be settled 100% in cash after the reporting person ceases to be a director of the Issuer."}],"balance_after":7486,"derivative":{"underlying":"Common Stock","underlying_shares":30.2201},"source":{"system":"sec-edgar","filing":"0001104659-16-146173","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/866121/000110465916146173/a4.xml","form_type":"4"}}]}